Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
RM Prins, X Wang, H Soto, E Young… - Journal of …, 2013 - journals.lww.com
Dendritic cell (DC) vaccination is emerging as a promising therapeutic option for malignant
glioma patients. However, the optimal antigen formulation for loading these cells has yet to
be established. The objective of this study was to compare the safety, feasibility, and
immune responses of malignant glioma patients on 2 different DC vaccination protocols.
Twenty-eight patients were treated with autologous tumor lysate (ATL)-pulsed DC
vaccination, whereas 6 patients were treated with glioma-associated antigen (GAA) peptide …
glioma patients. However, the optimal antigen formulation for loading these cells has yet to
be established. The objective of this study was to compare the safety, feasibility, and
immune responses of malignant glioma patients on 2 different DC vaccination protocols.
Twenty-eight patients were treated with autologous tumor lysate (ATL)-pulsed DC
vaccination, whereas 6 patients were treated with glioma-associated antigen (GAA) peptide …